Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2001-05-31
2008-12-16
Marvich, Maria (Department: 1633)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S455000, C435S091400, C435S091410, C435S091420, C424S093100, C424S093200, C424S093210, C424S093600, C514S04400A
Reexamination Certificate
active
07465583
ABSTRACT:
The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the invention. Methods of administering these reagents to a cell or subject are also described. Preferably, the parvovirus capsid is an AAV capsid. It is further preferred that the vector genome comprises AAV terminal repeat sequences.
REFERENCES:
patent: 6057152 (2000-05-01), Samulski et al.
patent: 6156303 (2000-12-01), Russell et al.
patent: 6596535 (2003-07-01), Carter
patent: WO 96/39530 (1996-12-01), None
patent: WO 98/48005 (1998-10-01), None
patent: WO 99/11802 (1999-03-01), None
patent: WO 00/24917 (2000-05-01), None
patent: WO 01/11034 (2001-02-01), None
patent: WO 01/11067 (2001-02-01), None
Wang et al Adeno-Associated Virus Type 2 DNA Replication In Vivo: Mutation Analyses of the D sequence in Viral Inverted Terminla Repeats, JVI, 1997, vol. 71(4), pp. 3077-3082.
Kmiec, E.B. Gene Therapy. May-Jun. 1999. American Scientist, vol. 87, pp. 240-247.
Anderson, W.F, Human Gene Therapy. Apr. 1998. Nature, vol. 392, pp. 25-30.
Verma, I.M. and Somia, N. Gene Therapy- promises, problems and prospect. Sep. 1997. Nature, vol. 389, pp. 239-242.
Meng R.D. and El-Deiry, W.S. Tumor Suppressor Genes as Targets for Cancer Gene Therapy. 1999. Gene Therapy of Cancer,Chapter 1. pp. 3-18.
Brister et al., “Mechanism of Rep-Mediated Adeno-Associated Virus Origin Nicking,”Journal of Virology74(17): 7762-7771 (2000).
Brister et al., “Rep-Mediated Nicking of the Adeno-Associated Virus Origin Requires Two Biochemical Activities, DNA Helicase Activity and Transesterification,”Journal of Virology73(11): 9325-9336 (1999).
Chiorini et al., “Cloning and Characterization of Adeno-Associated Virus Type 5,”Journal of Virology73(2): 1309-1319 (1999).
de la Maza et al., “Heavy and Light Particles of Adeno-Associated Virus,”Journal of Virology33(3): 1129-1137 (1980).
de la Maza et al., “Molecular Structure of Adeno-associated Virus Variant DNA,”The Journal of Biological Chemistry3194-3203 (Apr. 10, 1980).
Ferrari et al., “Second-Strand Synthesis is a Rate-Limiting Step for Efficient Transduction by Recombinant Adeno-Associated Virus Vectors,”Journal of Virology70(5): 3227-3234 (1996).
Fisher et al., “Transduction with Recombinant Aden-Associated Virus for Gene Therapy is Limited by Leading-Strand Synthesis,”Journal of Virology70(1): 520-532 (1996).
Hirata et al., “Design and Packaging of Adeno-Associated Virus Gene Targeting Vectors,”Journal of Virology74 (10): 4612-4620 (2000).
Muzyczka, “Use of AAV as a General Transduction Vector for Mammalian Cells,”Current Topics in Microbiology and Immunology158: 97-129 (1992).
Snyder et al., “Features of the Adeno-Associated Virus Origin Involved in Substrate Recognition by the Viral Rep Protein,”Journal of Virology67(10): 6096-6104 (1993).
Snyder et al., “In vitro Resolution of Covalently Joined AAV Chromosome Ends,”Cell60: 105-113 (1990).
Toulson et al., “Production and Improved Transduction Kinetics of Self-Complementary Adeno-Associated Viral Vectors,”Abstract#1858.
Toulson et al., 42ndAnnual Meeting of the American Society of Hematology, San Francisco, CA (Dec. 1-5, 2000). Published inBlood96(11): Part I, p. 432a (Nov. 16, 2000).
McCarty et al., “Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis,”Gene Therapy8: 1248-1254 (2001).
Ryan et al.; “Sequence Requirements for Binding of Rep68 to the Adeno-Associated Virus Terminal Repeats”,Journal of Virology, 1996, 1542-1553.
Snyder et al.; “Features of the Adeno-Associated Virus Origin Involved in Substrate Recognition by the Viral Rep Protein”,Journal of Virology, 1993, 6096-6104.
Wang et al.; “A Novel Terminal Resolution-Like Site in the Adeno-Associated Virus Type 2 Genome”,Journal of Virology, 1997, 1140-1146.
Wang et al.; “Rescue and Replication of Adeno-Associated Virus Type 2 as well as Vector DNA Sequences from Recombinant Plasmids Containing Deletions in the Viral Inverted Terminal Repeats: Selective Encapsidation of Viral Genomes in Progeny Virions”,Journal of Virology, 1996, 1668-1677.
Wang et al.; “Rescue and Replication Signals of the Adeno-associated Virus 2 Genome”,J. Mol. Biol., 1995: 250, 573-580.
Ward et al.; “In Vitro Rescue of an Integrated Hybrid Adeno-associated Virus/Simian Virus 40 Genome”,J. Mol. Biol., 1991: 218, 791-804.
Ward et al.; “Short Communication”,Virology, 1995: 209, 692-695.
European Search Report, European Application No. EP 05076932.2, dated Mar. 17, 2006 (8 pages).
Bishop et al., “Role of the Terminal Repeat GAGC Trimer, the Major Rep78 Binding Site, In Adeno-Associated Virus DNA Replication”,Febs Letters, 397, 1996, p. 97-100.
McCarty et al.; “Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo”,Gene Therapy, 2003: 10(26), p. 2112-2118.
Wang et al.; “Adeno-associated virus type 2 DNA replication in vivo: mutational analyses of the D sequence in viral inverted repeats”,Journal of Virology, 1997: 71(4), p. 3077-3082.
Hauswirth et al. “Adeno-Associated Virus DNA Replication: Nonunit-Length Molecules”Virology93: 57-68 (1979).
McCarty Douglas M.
Samulski Richard Jude
Marvich Maria
Myers Bigel Sibley & Sajovec P.A.
The University of North Carolina at Chapel Hill
LandOfFree
Duplexed parvovirus vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Duplexed parvovirus vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Duplexed parvovirus vectors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4039297